Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Friday, 06'th Oct 2023
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IPOs are out of fashion. Here's what companies are doing instead.
11:39am, Friday, 06'th Oct 2023
While the current deal landscape on Wall Street remains low on M&A, initial public offerings (IPOs), and other transactions, corporate spinoffs are chugging along.
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
08:27am, Friday, 06'th Oct 2023
With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, a
Johnson & Johnson stock price forecast: RBC analyst sees a 15% upside
12:30pm, Thursday, 05'th Oct 2023
Johnson & Johnson (NYSE: JNJ) is trading just above its year-to-date low at writing – which creates an opportunity to invest in a quality name at a discount, as per an RBC Capital Markets analyst. J
3 Ways AI Can Help Healthcare Companies Grow
08:00am, Thursday, 05'th Oct 2023
The healthcare industry is full of manual processes that could benefit from AI. AI can help improve outcomes for patients while also growing revenue for businesses.
2 Magnificent Dividend Kings to Buy Now
06:00am, Thursday, 05'th Oct 2023
Coca-Cola and J&J both have long track records of increasing dividend payments to shareholders. These companies also offer bright earnings prospects well into the future, thanks to their solid product
3 Historically Cheap Dow Stocks to Buy Hand Over Fist in October
05:21am, Thursday, 05'th Oct 2023
The Dow Jones Industrial Average is home to 30 generally profitable, diverse, multinational businesses. A pullback in the Dow from its 2023 high is the perfect opportunity for long-term investors to b
7 Top Healthcare Stocks That Pay Dividends
08:08pm, Wednesday, 04'th Oct 2023
Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the ec
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
10:31am, Wednesday, 04'th Oct 2023
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment
12:05pm, Tuesday, 03'rd Oct 2023
Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.
Court tosses $223.8 million verdict against J&J in talc cancer case
10:10am, Tuesday, 03'rd Oct 2023
A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson in a trial over four plaintiffs' claims that they developed cancer from being exposed to the company'
Court tosses $223.8 million verdict against J&J in talc cancer case
09:51am, Tuesday, 03'rd Oct 2023
A New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson in a trial over four plaintiffs' claims that they developed cancer from being exposed to the company'
Drugmakers opt in to Medicare drug price negotiations – here's what happens next
03:34pm, Monday, 02'nd Oct 2023
The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
12:01pm, Monday, 02'nd Oct 2023
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
